276 related articles for article (PubMed ID: 38224708)
1. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
2. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
3. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV
Lancet HIV; 2022 Jun; 9(6):e414-e427. PubMed ID: 35659336
[TBL] [Abstract][Full Text] [Related]
5. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study.
Smit C; Boyd A; Rijnders BJA; van de Laar TJW; Leyten EM; Bierman WF; Brinkman K; Claassen MAA; den Hollander J; Boerekamps A; Newsum AM; Schinkel J; Prins M; Arends JE; Op de Coul ELM; van der Valk M; Reiss P;
Lancet HIV; 2021 Feb; 8(2):e96-e105. PubMed ID: 33357835
[TBL] [Abstract][Full Text] [Related]
6. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
[TBL] [Abstract][Full Text] [Related]
7. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020.
Harney BL; Sacks-Davis R; van Santen DK; Traeger MW; Wilkinson AL; Asselin J; Fairley CK; Roth N; Bloch M; Matthews GV; Donovan B; Guy R; Stoové M; Hellard ME; Doyle JS
Liver Int; 2024 Apr; 44(4):1024-1031. PubMed ID: 38291946
[TBL] [Abstract][Full Text] [Related]
9. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
10. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
Pineda JA; Núñez-Torres R; Téllez F; Mancebo M; García F; Merchante N; Pérez-Pérez M; Neukam K; Macías J; Real LM;
J Infect; 2015 Nov; 71(5):571-7. PubMed ID: 26212868
[TBL] [Abstract][Full Text] [Related]
13. Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis.
Munari SC; Traeger MW; Menon V; Latham NH; Manoharan L; Luhmann N; Baggaley R; MacDonald V; Verster A; Siegfried N; Conway B; Klein M; Bruneau J; Stoové MA; Hellard ME; Doyle JS
Liver Int; 2023 Dec; 43(12):2625-2644. PubMed ID: 37817387
[TBL] [Abstract][Full Text] [Related]
14. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV
Clin Infect Dis; 2020 Sep; 71(6):1502-1510. PubMed ID: 31585005
[TBL] [Abstract][Full Text] [Related]
15. The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals.
Chromy D; Bauer DJM; Simbrunner B; Jachs M; Hartl L; Schwabl P; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Mandorfer M; Gschwantler M; Reiberger T
J Viral Hepat; 2022 May; 29(5):385-394. PubMed ID: 35274399
[TBL] [Abstract][Full Text] [Related]
16. Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study.
Marshall AD; Martinello M; Treloar C; Matthews GV
Int J Drug Policy; 2022 Nov; 109():103828. PubMed ID: 35994937
[TBL] [Abstract][Full Text] [Related]
17. Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019.
van Santen DK; Sacks-Davis R; Stewart A; Boyd A; Young J; van der Valk M; Smit C; Rauch A; Braun DL; Jarrin I; Berenguer J; Lazarus JV; Lacombe K; Requena MB; Wittkop L; Leleux O; Salmon D; Bonnet F; Matthews G; Doyle JS; Spelman T; Klein MB; Prins M; Asselin J; Stoové MA; Hellard M;
EClinicalMedicine; 2023 Feb; 56():101810. PubMed ID: 36618902
[TBL] [Abstract][Full Text] [Related]
18. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
[TBL] [Abstract][Full Text] [Related]
19. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
[TBL] [Abstract][Full Text] [Related]
20. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]